undamentalytics Newsletter
Sign in

Lexaria Bioscience Corp. (LEXX) stock

Add to watchlist

Add holding +

NASDAQ: LEXX Nasdaq Biotechnology

Lexaria Bioscience Corp. is a US-listed company in the biotechnology industry. Its financial year ends in August.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

Not valued: the figures our models need are missing or failed our data-quality checks.

Price vs value

No model value: limited reported history: available models are shown without a Buy/Hold/Sell rating. How we value companies.

Lexaria Bioscience Corp. valuation: adjust assumptions and compare models →

The Fundamentalytics view

Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 33% in the quarter to 2026-05-31.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Lexaria Bioscience Corp.'s latest figures clears our strength thresholds.

Things to watch

  • Volatile shares. Over the past year the shares showed annualised volatility of 127% and a beta of 0.9 against the S&P 500.
  • Heavily shorted. 12.5% of the shares available to trade are sold short (3.3 days of average volume to cover).

Latest results

Earnings per share
-$1.20 against an average estimate of -$0.90: missed by 33.3%

Lexaria Bioscience's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+11.0%
  • 1 week+25.5%
  • 1 month+40.3%
  • This year-60.7%
  • 1 year-74.1%
  • 5 years-95.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Agreement
  2. Announcement
  3. Announcement
  4. Governance

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Lexaria Bioscience Corp. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value Lexaria Bioscience Corp. as an operating company, with every model that fits that kind of business. Cost of equity 9.2%: the 10-year Treasury yield (4.9%) plus a beta of 0.95 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no twelve-month earnings or share count in the filings yet
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: no twelve-month earnings or share count in the filings yet
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: no twelve-month earnings or share count in the filings yet
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — Does not apply: no twelve-month earnings or share count in the filings yet
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. — No model applies: the filings don’t yet support a value.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Lexaria Bioscience Corp. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$4.05 +59% $20000 −97%
Next −$4.65 −15% $1m +6915%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +3.8% on 90 days ago. In the last 30 days, 0 analysts raised Lexaria Bioscience Corp.'s forecast and 1 cut it.

Consensus EPS forecast Lexaria Bioscience Corp., last 90 days
−$6.00 −$4.00 −$2.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$3.90 Current fiscal year, 60 days ago: −$3.90 Current fiscal year, 30 days ago: −$3.90 Current fiscal year, 7 days ago: −$3.90 Current fiscal year, Now: −$4.05 −$4.05 Next fiscal year, 90 days ago: −$4.65 Next fiscal year, 60 days ago: −$4.65 Next fiscal year, 30 days ago: −$4.65 Next fiscal year, 7 days ago: −$4.65 Next fiscal year, Now: −$4.65 −$4.65

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$3.90−$4.65
60 days ago −$3.90−$4.65
30 days ago −$3.90−$4.65
7 days ago −$3.90−$4.65
Now −$4.05−$4.65

Earnings against estimates

Quarter toEstimateActualSurprise
May 2026 −$0.90 −$1.20 −33.3%
Feb 2026 −$1.05 −$0.90 +14.3%
Nov 2025 −$1.95 −$1.05 +46.2%
Aug 2025 −$2.35 −$1.95 +17.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Positioning

Short interest
12.5%
of tradable shares
Days to cover
3.34
at average volume
Short interest, 1 month
+43%
to October 15, 2026
Held by institutions
5%
of shares
Held by insiders
2.6%
of shares
Employees
7
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 20222023202420252026 to date
Return
LEXX−39%−49%+68%−71%−61%
Industry peers (median)−57%−17%−29%−5%−26%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
LEXX25%42%50%42%46%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
LEXX−60%−80%−68%−77%−84%
S&P 500−25%−10%−8%−19%−9%

Worst fall since January 12, 2021: 98% from July 21, 2021 to October 19, 2026. Getting back needed a 4769% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$2.60 – $20.10
From 52-week high
−81.9%
vs 50-day average
−29.0%
vs 200-day average
−59.2%
Volatility (1 year)
127%
Beta vs S&P 500
0.92

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Where the revenue comes from

Fiscal year to August 31, 2025
Products and services
Line of business Revenue Share YoY
IP Licensing $696,000 98.6% ▲ 52.0%
B Two B $9,923 1.4% ▲ 84.2%
Other Revenue $0 0.0% ▼ 100.0%

From Lexaria Bioscience Corp.'s 10-K filed November 28, 2025, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

Data status

When each part of this page on Lexaria Bioscience Corp. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Lexaria Bioscience Corp. in brief

What does Lexaria Bioscience Corp. do?
Lexaria Bioscience Corp. is a US-listed company in the biotechnology industry. Its financial year ends in August.
What is Lexaria Bioscience Corp.'s stock ticker?
Lexaria Bioscience Corp. trades under the ticker LEXX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.